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Abstract
Aim/hypothesis Low-grade inflammation may contribute to
obesity-related insulin resistance and has been associated
with increased risk of type 2 diabetes mellitus. The present
study evaluated whether treatment with salsalate, a tradi-
tional anti-inflammatory medication, would improve insulin
action in obese non-diabetic individuals.
Methods The study was a randomised, double-blind, placebo-
controlled, parallel trial conducted at the inpatient clinical
research unit of the NIDKK (Phoenix, AZ, USA). Participants
were 54 adults (18 to 45 years of age) with BMI≥30 kg/m2.
The intervention was salsalate (3 g/day, n=28) or identical
placebo (n=26) for 7 days. The allocation was kept
concealed by giving the investigator only a number
corresponding to a vial of placebo or salsalate sequentially
randomised in blocks by sex. Main outcomes were changes
in insulin action assessed as rate of glucose disposal (Rd) by
euglycaemic–hyperinsulinaemic clamp (insulin infusion rate
40 mU m−2 min−1) and glucose tolerance by 75 g OGTT.
Results The study was completed by 47 participants, of
which 40 were analysed (salsalate n=22, placebo n=18).
Salsalate treatment resulted in decreased fasting plasma
glucose concentration (mean [SD]; 4.83 [0.28] vs 5.11
[0.33] mmol/l, p=0.001) and glucose AUC during the
OGTT (p=0.01), and in increased Rd (20 [8] vs 18 [6] µmol
[kg estimated metabolic body size]−1 min−1, p=0.002),
while there was no significant change in these variables
with placebo (p>0.3 for all). The effect of salsalate on Rd
disappeared (p=0.9) after normalising to increased insulin
concentrations (701 [285] vs 535 [201] pmol/l, p<0.0001)
measured during the clamp. No side effects of salsalate
were observed during the study.
Conclusions/interpretation The glucose-lowering potential
of salicylates appears to be due to effects on insulin
concentration rather than improved insulin action. Salicy-
late-based compounds may be useful for the treatment and
prevention of type 2 diabetes.
Trial registration: ClinicalTrials.gov NCT 00339833.
Funding: Intramural research programme of the NIDDK/
NIH/DHHS.
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Introduction
Obesity is a condition characterised by chronic activation of
the innate immune system [1]. This subclinical activation
has been implicated in the development of metabolic
complications of obesity such as insulin resistance and
type 2 diabetes mellitus [2–4]. Treatment of inflammation is
a potential novel strategy in prevention and treatment of
type 2 diabetes [5].
Administration of salicylates, traditional anti-inflammatory
drugs, has been known to reduce hyperglycaemia in patients
with pre-existing diabetes [6–8]. Indeed, not only do salic-
ylates reduce fasting systemic glucose concentrations, they
also improve systemic glucose concentrations following oral
glucose, a mixed meal and an intravenous insulin challenge
in diabetic and non-diabetic patients [9–14]. Moreover, in
diabetic and non-diabetic patients, improvement of glucose
tolerance was observed within 1 week of treatment with
aspirin (chemically, acetylsalicylic acid) [10, 12]. In exper-
imental animal models, salicylates lowered plasma glucose
and insulin concentrations during an OGTT [15].
The mechanisms underlying the glucose-lowering effect
of salicylates have not been defined and studies remain
conflicting. In 3T3-L1 adipocytes and FaO hepatoma cells,
pre-treatment with high doses of salicylates reversed TNF-
α-induced cellular insulin resistance [15], while in rats
salicylates prevented hepatic and peripheral insulin resis-
tance induced by lipid infusion [16, 17]. Patients with type
2 diabetes showed decreased endogenous glucose produc-
tion (EGP) and increased insulin-mediated glucose disposal
when administered a high anti-inflammatory dose of
acetylsalicylic acid [12]. In healthy participants, acute pre-
treatment with aspirin attenuated lipid-induced impairment
of insulin action [18], but had no effect on insulin resistance
induced by prolonged fasting [19]. However, other studies
in healthy individuals indicated that the stimulatory effect
of salicylates on glucose utilisation is caused by increased
systemic availability of insulin, in spite of unchanged or
even decreased peripheral insulin sensitivity [20–22].
The nuclear factor-κB (NF-κB) has been proposed as a
molecular target mediating the glucose-lowering effect of
salicylates [5]. NF-κB is a transcription factor that stimulates
expression of numerous genes whose products may alter
insulin action [5]. NF-κB is maintained in the cytoplasm
through interaction with inhibitory proteins, the IκBs,
which are rapidly degraded upon phosphorylation by IκB
kinase (IKK) [23]. The inhibitory effect of salicylates on
NF-κB activation is presumed to be mediated via inhibition
of IKKβ activity [24]. In fact, administration of salicylates
prevented hepatic and peripheral insulin resistance in mice
with genetically increased IKKβ levels in the liver [25].
Since chronic low-grade inflammation is a hallmark of
obesity [1] and contributes to increased risk of insulin
resistance and type 2 diabetes [4], we investigated whether
use of a common anti-inflammatory dose of salsalate (3 g
per day) in non-diabetic obese individuals (BMI≥30 kg/m2)
would improve insulin action as measured by the eugly-
caemic–hyperinsulinaemic clamp method and whether
changes in insulin action were mediated via improvement
in inflammation, specifically the NF-κB/IKKβ inflamma-
tory pathway. Salsalate is a dimer of salicylic acid with an
established safety profile after many decades of use to treat




The study was double-blind and placebo-controlled in
design. Eligible participants were between 18 and 45 years,
had a BMI≥30 kg m−2 and were non-diabetic by OGTT
(1999 WHO criteria). All participants were non-smokers at
the time of the study and, except for obesity, healthy
according to medical history, physical examination and
routine laboratory tests. The protocol was approved by the
Institutional Review Board of the NIDDK and the Gila
River Indian Community tribal council. All participants
provided written informed consent before participation.
Study procedures
Upon admission to the clinical research unit at the NIDKK
(Phoenix, AZ, USA), all participants were placed on a weight-
maintaining diet (containing 50% of energy as carbohydrate,
30% as fat and 20% as protein). Body composition was
measured by dual-energy x-ray absorptiometry (GE/Lunar,
Madison, WI, USA). At least 3 days after admission and after
a 12 h overnight fast a 2-h 75 g OGTT was performed to
exclude diabetes.
One day after the OGTT, a euglycaemic–hyperinsulinaemic
clamp was performed to assess insulin action at physiolog-
ical hyperinsulinaemia [26]. Briefly, after an overnight fast
a catheter was placed in the antecubital vein and a primed
(1.11 MBq) continuous (0.01 MBq/min) [3-3H]glucose in-
fusion was started to determine EGP. A second catheter was
inserted retrogradely into a vein on the dorsum of the hand
for blood sampling and the hand was placed in a heated box
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(60°C) for the duration of the study. At least 2 h after
starting the [3-3H]glucose infusion, a primed continuous
intravenous insulin infusion was administered for 100 min
at a constant rate of 40 mU m−2 min−1. Arterialised blood
samples were collected every 5 min for plasma glucose
determination and a 20% glucose infusion was adjusted to
maintain the plasma glucose concentration at about
5.6 mmol/l. Blood samples for measurement of [3-3H]
glucose specific activity and plasma glucose and serum
insulin concentrations were collected at the end of the basal
period (22, 15, 8 and 1 min prior to insulin infusion) and
every 10 min during the final 40 min of insulin infusion.
Under fasting conditions, the rate of glucose appearance
(Ra) was calculated as the [3-
3H]glucose infusion rate
divided by the steady-state plasma [3-3H]glucose specific
activity. During the insulin clamp, Ra was calculated from
Steele's non-steady-state equation [27]. EGP was calculated
as the difference between Ra and the exogenous glucose
infusion rate (GIR) corrected for changes in glucose
concentrations. The rate of glucose disposal (Rd) was
defined as the average sum of GIR and EGP during the
last 40 min of the insulin infusion. Rd was further corrected
for individual variation in average plasma glucose and
serum insulin concentrations during the last 40 min of the
clamp [26, 28] by normalising to reference values of
5.55 mmol/l for glucose and 280 pmol/l for insulin
(~ED50 of insulin-stimulated whole-body glucose disposal
standardised to current insulin assay) [29]. GIR, EGP and
Rd were further normalised to estimated metabolic body
size (EMBS), which is directly derived from fat-free mass
but takes into account the intercept of the relation between
metabolic rate and fat-free mass (−17.7 kg in our laboratory
[i.e. EMBS=fat-free mass+17.7 kg]) [30]. The metabolic
clearance rate of insulin was defined as insulin infusion rate
divided by incremental (clamp minus basal) serum insulin
concentration during the last 40 min of the insulin infusion.
Randomisation
One day after the clamp, participants were randomly
assigned to receive orally 3 g/day salsalate (Salsalate;
Pliva, Zagreb, Croatia) or identical placebo divided in two
doses for 7 days. Participants and research personnel were
blinded to the assignment. Tolerance of the medication was
evaluated daily by questionnaire and monitoring vital signs.
The OGTT was repeated on day 6 of medication and the
euglycaemic–hyperinsulinaemic clamp was repeated on
day 7 with the last dose of the medication being
administered 1 h prior to the start of the insulin infusion.
Serum salicylate concentrations were drawn 1 h prior to the
final dose of medication. Out of 54 participants rando-
mised, seven did not complete the second OGTT due to
voluntary withdrawal (n=3, one of which assigned to
salsalate), toothache, indigestion, chest pain and minor
infection (all assigned to placebo). Six participants did not
complete second clamp because of poor venous access (n=
4, two from each treatment group), anaemia or excess drop
in glycaemia during insulin infusion (3.8 mmol/l) (both
from the salsalate group). One participant from the salsalate
group was not included in the analysis due to an error in
preparation of the isotope solution. Details on withdrawals,
see Fig. 1 in the Electronic supplementary material (ESM).
Laboratory measurements
Plasma glucose concentrations were determined by the
glucose oxidase method (Beckman Instruments, Fullerton,
CA, USA). Insulin concentrations in plasma (OGTT) or
serum (clamp) were measured by an automated immunoas-
say (Access; Beckman Instruments). Commercial ELISA
was used to determine concentrations of inflammatory
markers (C-reactive protein [CRP] and monocyte chemo-
attracting protein 1) and adiponectin in plasma (Lincoplex;
Millipore, Billerica, MA, USA), and NEFA in serum (Wako
Chemicals, Richmond, VA, USA). Serum salicylate con-
centration was determined by a colorimetric assay from
Dade Behring (Milton Keynes, UK).
The activity of the p65 subunit of NF-κB in isolated
monocytes from peripheral blood was measured in a
subgroup of 20 participants (ten from each group). Briefly,
peripheral blood mononuclear cells (PBMC) were isolated
from whole blood using Ficoll-Paque Plus density centri-
fugation (Amersham Biosciences, Uppsala, Sweden). The
PBMC pellet was resuspended in 90% fetal bovine serum
with 10% DMSO (vol./vol) and stored at −80°C until
shipment on dry ice. Thawed PBMC samples were washed
in excess PBS (pH 7.4) and centrifuged (400×g, 5 min, 4°C),
to remove residual fetal bovine serum and DMSO. The
supernatant fraction was discarded and the pellets resus-
pended in 100 μl of triple detergent buffer (50 mmol/l Tris
HCl pH 8.0; 150 mmol/l NaCl; 0.02% NaN3; 0.1% SDS;
100 μg/ml PMSF; 1 μg/ml aprotinin; 1% nonidet P-40;
0.5% sodium deoxycholate (wt/vol.), in Milli-Q H2O
[Millipore]). The samples were then sonicated for 1 min
and centrifuged (400×g, 3 min, 4°C). The resulting
supernatant fraction was used for the DNA binding assay
outlined below to assess p65, NFκB activity. The protein
concentration of all protein isolates was determined using a
protein assay (Bicinchoninic Acid assay; Pierce, Rockford,
IL, USA) performed according to manufacturer’s instruc-
tions. The TransAM NF-κB DNA-binding activity assay
(Active Motif, Carlsbad, CA, USA) was used to detect and
quantify the activity of the p65 subunit of NF-κB. Nuclear
extracts from PBMC (30 µg protein per well) were
analysed for their binding capacity to an NF-κB consensus
sequence in labelled DNA in a 96-well plate format. The
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assays were performed according to manufacturer’s instruc-
tions. Absorbance was measured on a Victor3 Multilabel
plate reader (Perkin Elmer, Wellesley, MA, USA). Results
are expressed as ng p65 activity/μg protein.
Concentrations of adiponectin and inflammatory markers
in plasma, and of NEFA and salicylates in serum, as well as
NF-κB activity in PBMC were measured from fasting blood
samples drawn at the baseline OGTT and just prior to the
isotope bolus of the second euglycaemic–hyperinsulinaemic
clamp.
Sample size calculation
Sample size was estimated using Rd values of obese non-
diabetic participants who underwent a euglycaemic–hyper-
insulinaemic clamp in a longitudinal study of the aetiology
of type 2 diabetes mellitus [31]. Based on recent data (J. C.
Bunt, unpublished observation), the log-transformed mean
and standard deviation of Rd in this study population was
1.15 and 0.12 µmol [kgEMBS]
−1 min−1, respectively, and the
correlation between two measurements in the same indi-
vidual was 0.88. Assuming equal correlation between
placebo and treatment groups, the SD of the difference in
logarithms of Rd values was calculated as 0.059. To find a
difference of 0.06 in the log of Rd values, a sample size of
17 in each group was needed to have 80% power at an
alpha of 0.05.
Statistical analyses
Statistical analyses were performed using software of the
SAS Institute (version 8.02; Cary, NC, USA). Since the
primary outcome was the change in Rd from baseline
between the salsalate and placebo group, only participants
who completed both clamps were included in the analyses.
Secondary outcomes were changes in inflammatory
markers, glucose tolerance, insulin secretion and hepatic
insulin action, as well as the association between the
markers of inflammation and metabolic characteristics of
the study population. Based on the data distribution,
parametric or non-parametric tests were used to compare
baseline characteristics of the two groups (unpaired test)
Table 1 Baseline characteristics of the study population by treatment group
Characteristic Placebo Salsalate p value
n 18 22 –
Men/women (n) 9/9 10/12 1.0
Ethnicity (W/N/H) 3/14/1 3/19/0 0.6
Age (years) 33 (8) 29 (7) 0.2
BMI (kg/m2) 38 (6) 37 (5) 0.7
Body fat (%) 38 (7) 38 (6) 0.9
Fasting plasma glucose (mmol/l) 5.06 (0.33) 5.11 (0.33) 0.9
2 h plasma glucose (mmol/l) 6.61 (1.83) 6.67 (1.17) 0.9
Fasting plasma insulin (pmol/l) 63 (49, 90) 80 (56, 104) 0.3
Basal EGP (μmol [kgEMBS]
−1 min−1) 11 (2) 10 (2) 0.2
Clamp EGP (μmol [kgEMBS]
−1 min−1) 0 (0, 3) 0 (0, 2) 0.8
Clamp Rd (μmol [kgEMBS]
−1 min−1)a 16 (13, 20) 13 (11, 15) 0.09
Unless otherwise stated, data are means (SD) or medians (25th, 75th percentile)
aRd normalised for steady-state plasma glucose and serum insulin concentrations
p values were determined by Mantel–Haenszel test on categories, Student’s t test on means and Wilcoxon’s U test on medians; W, Whites; N,
Native Americans; H, Hispanics
Fig. 1 Plasma glucose and insulin concentrations (means and SD)
during an OGTT at baseline (white circles) and after 6 days of
treatment (black circles) with placebo (a, c) or salsalate (b, d).
Repeated-measures ANOVA was used to test for the effects of time
(p<0.0001 all models) and visit (follow-up vs baseline; glucose: p=0.2
after placebo, p=0.01 after salsalate; insulin: p=1.0 both), and for the
visit × time interaction within each treatment group (glucose: p=0.9
placebo, p=0.4 salsalate; insulin: p=1.0 both groups). Between-group
comparison (ANCOVA): group (placebo vs salsalate) × visit, p=
0.007; group × visit × time, p=0.8
388 Diabetologia (2009) 52:385–393
and to compare the response to treatment within each group
(paired test). The effect of two treatments was compared by
analysis of covariance (ANCOVA) using the MIXED proce-
dure in SAS. The values of non-normally distributed variables
were logarithmically transformed to approximate normal
distribution. Spearman correlation was used to test for simple
associations between the variables. Two-tailed p values less
than 0.05 were considered to be statistically significant.
Results
A total of 40 participants completed the study, 22 were
assigned to salsalate and 18 to placebo. Baseline clinical
characteristics of the two groups were not significantly
different (Table 1), although it should be noted that there
was a trend towards higher Rd in the placebo group. After
7 days of treatment, serum salicylate concentration was
increased in all participants receiving salsalate (range 41–
232 mg/l) and remained undetectable in all participants
treated with placebo (<14 mg/l) (to convert plasma salicylate
values in mg/l to mmol/l multiply by 0.00724).
Oral glucose tolerance test After the treatment, fasting
plasma glucose concentration was significantly decreased
in the salsalate group (by mean 4.7 [SD 6.5]% vs baseline,
p=0.001) and remained unchanged in the placebo group
(p=0.9) (p=0.002 for between-groups comparison). The
2 h plasma glucose concentration was not significantly
changed in any treatment group (p=0.2 salsalate, p=0.6
placebo; p=0.2 between-groups comparison) (Fig. 1). In
repeated measures ANOVA we observed a significant
overall lowering of glucose concentrations after treatment
in the salsalate group (p=0.01); the effect of treatment on
glucose concentration did not significantly vary across the
time course of glucose responses to OGTT, i.e. there was no
significant treatment×time interaction (Fig. 1). Administra-
tion of placebo or salsalate had no significant effect on plasma
insulin concentrations during OGTT (Fig. 1). The effect of
salsalate on plasma glucose and insulin concentrations was
similar in men and women. Neither changes (follow-up vs
baseline) in fasting plasma glucose concentration (r=0.11,
p=0.6) nor changes in glucose AUC during OGTT (r=0.01,
p=1.0) were associated with follow-up serum salicylate
concentrations in the salsalate group (r=0.17, p=0.5).
Euglycaemic–hyperinsulinaemic clamp As illustrated by
Fig. 2, the average serum insulin concentration during the
last 40 min of the clamp was significantly increased at
follow-up in the salsalate group. Metabolic clearance of
insulin was decreased after treatment with salsalate (0.55
[0.19] vs 0.70 [0.22] l/min, p<0.0001) and unchanged after
placebo (0.80 [0.27] vs 0.74 [0.17] l/min, p=0.8). The
salsalate group also showed a significant increase in the
GIR (Fig. 2). Because of the unchanged rate of EGP (0.93
[1.84] vs 1.13 [1.50] μmol [kgEMBS]
−1 min−1, follow-up vs
baseline, p=0.5), Rd was also increased after the treatment
with salsalate (Fig. 2). The effect of salsalate on clamp
insulin concentration, GIR and Rd remained different from
the effect of placebo in the between-group comparison
(Fig. 2). However, the effect of salsalate on Rd was
completely abolished after normalising to average serum
insulin concentrations during the clamp (14 [3.61] μmol
Fig. 2 Changes in: a serum insulin concentration (ΔSSSI; p=0.6
placebo, p<0.0001 salsalate, follow-up vs baseline by paired t test; p<
0.0001 placebo vs salsalate by ANCOVA); b GIR (ΔGIR; p=0.9
placebo, p=0.004 salsalate; p=0.04 placebo vs salsalate); c EGP
(ΔEGP; p=0.3 placebo, p=0.5 salsalate; p=0.9 placebo vs salsalate);
and d Rd (ΔRd, adjusted for steady-state glucose; p=0.7 placebo, p=
0.003 salsalate; p=0.02 placebo vs salsalate) during euglycaemic
hyperinsulinaemia after treatment with placebo or salsalate. Data
boxes display median (solid line), mean (dotted line), quartiles (box),
and 10th and 90th percentiles (error bars)
Fig. 3 Change in Rd and serum insulin concentration from fasting
state to euglycaemic hyperinsulinaemia at baseline (white circles) and
after 7 days of treatment (black circles) with placebo (a) or salsalate
(b) demonstrating that the increase in Rd during the clamp is directly
associated with the increase in insulin concentration. Fasting Rd was
assumed to be equal to the Ra (steady-state assumption) and clamp Rd
was equal to M normalised to steady-state plasma glucose concentra-
tion. Data are shown as means (SE)
Diabetologia (2009) 52:385–393 389
[kgEMBS]
−1 min−1, follow-up and baseline, p=0.9). As
illustrated by Fig. 3, the average increase in Rd with
salsalate treatment was directly associated with the increase
in average insulin concentrations during the clamps,
indicating that the higher Rd in the salsalate group was
accounted for by the increased insulin concentrations.
However, it should also be noted that in a secondary
analysis, the difference in Rd between pre- and post-
treatment in the salsalate group was positively associated
with follow-up serum salicylate concentration both before
(Fig. 4) and after normalisation for clamp insulin concen-
trations (r=0.50, p=0.02). The effect of treatment on Rd or
EGP was not significantly affected by sex.
NEFA, adiponectin and inflammatory markers Neither
salsalate nor placebo administration was followed by
significant changes in body weight or circulating NEFA
concentrations (Table 2). Plasma adiponectin concentration
was significantly lower after the 1 week in the placebo
group but remained unchanged in the salsalate group
(Table 2). Salsalate treatment was followed by a significant
decrease in plasma CRP concentration (Table 2). There
were no changes in plasma monocyte chemoattracting
protein concentration in either group (Table 2). Between-
group comparisons showed a significant effect of treatment
on plasma adiponectin (p=0.04), but not on plasma CRP
concentration (p=0.08) and serum activities of aspartate
aminotransferase (p=0.3) and alanine aminotransferase
(p=0.5). Changes in CRP concentrations in the salsalate
group were not significantly related to follow-up serum
salicylate concentrations (r=−0.26, p=0.3).
NF-κB activity in PBMC In the subgroup of participants
with measurement of activity of the p65 subunit of NF-κB
in monocytes from peripheral blood (n=20, ten participants
in each group), p65 activity was not related to body fat
(r=0.25, p=0.3) and was negatively associated with Rd
(Fig. 4). The association between p65 activity and Rd at
baseline was weaker after normalisation of Rd to average
serum insulin concentration during the clamp (r=0.32,
p=0.15). Treatment with salsalate had no significant effect
on p65 activity in monocytes (p=0.2) (Fig. 4). No statis-
tically significant correlation was found between changes in
p65 activity and serum salicylate concentrations at follow-
up in the salsalate group (r=0.43, p=0.09). Compared with
the whole group, the effect of salsalate on glycaemia was in
a similar direction but not significant (p=0.2), while the
effect on serum insulin concentration during clamp and Rd
(p=0.009, adjusted for glucose; p=0.4, adjusted for glucose
and insulin) was similar.
Table 2 The effect of placebo or salsalate on metabolic characteristics and inflammatory markers
Characteristic Placebo (n=18) Salsalate (n=22)
Baseline Follow-up Baseline Follow-up
Body weight (kg) 103 (89, 118) 103 (89, 117) 109 (93, 114) 109 (93, 114)
NEFA (μmol/l) 385 (320, 430) 390 (320, 440) 345 (295, 500) 435 (385, 500)
Adiponectin (mg/l) 4.3 (3.7, 5.7) 3.5 (2.8, 5.1)a 5.2 (4.0, 7.5) 5.2 (3.2, 6.9)
hsCRP (ng/l) 55 (33, 120) 60 (20, 108) 63 (16, 89) 39 (12, 69)a
MCP-1 (ng/l) 118 (99, 152) 119 (110, 132) 109 (92, 165) 109 (80, 141)
Data are medians (25th, 75th percentile)
a p<0.05 (Wilcoxon’s signed ranks test)
hsCRP, high sensitivity C-reactive protein; MCP-1, monocyte chemoattracting protein 1
Fig. 4 a Spearman correlation between NF-κB activity (expressed as
activity of p65 subunit) and Rd at baseline (normalised to steady-state
plasma glucose concentration). r=−0.56; p=0.009. b The effect of
treatment on NF-κB activity (n=10 per group). c Spearman correlation
of changes (follow-up minus baseline) in Rd (normalised to steady-
state plasma glucose concentration) and (d) NF-κB activity with
serum salicylate concentrations at follow-up. r=0.47, p=0.03 (c).
Black circles/bars, salsalate; white circles/bars, placebo; solid line,
linear regression line; dotted line, 95% CI. (To convert plasma
salicylate values in mg/l to mmol/l multiply by 0.00724)
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Discussion
The glucose-lowering effect of salicylates has been
known for decades [6–8]. In this randomised double-blind
placebo-controlled trial in non-diabetic, healthy obese
individuals, administration of a therapeutic dose of salsalate
for 1 week decreased fasting plasma glucose (by ~5 %) as
well as glucose, but not insulin concentrations during the
OGTT. Salsalate improved apparent peripheral insulin
action as measured by glucose disposal during the
euglycaemic–hyperinsulinaemic clamp, but this effect was
entirely due to increased serum insulin concentrations
during the clamp.
Intravenous administration of lysine acetylsalicylate
increased insulin concentration in the fasting state and
following various secretagogues [32]. A recent placebo-
controlled study in non-diabetic individuals showed re-
duced C-peptide and unchanged insulin response during
OGTT in non-diabetic individuals receiving salsalate [13].
Although the authors of that study interpreted these results
as improvement in insulin action, their findings could just
as well indicate decreased insulin clearance. Treatment with
salsalate in our study significantly increased systemic in-
sulin concentration during a euglycaemic–hyperinsulinae-
mic clamp despite no differences in insulin infusion rates.
This is similar to the previously reported effect of aspirin
[20], where increased insulin concentrations after aspirin
were accompanied by unchanged C-peptide levels indicat-
ing lower insulin clearance. Although changes in insulin
clearance appear to be the most plausible explanation of
increased insulin concentration, incomplete suppression of
endogenous insulin production may be an additional
contributor. In fact, increasing the dose of the salicylate
derivative triflusal was followed by reduced fasting plasma
glucose concentration, unchanged insulin effectiveness and
augmented insulin response during frequently sampled
intravenous glucose tolerance test in a recent double-blind
crossover placebo-controlled study in obese non-diabetic
individuals [33]. Furthermore, the authors of that study
performed additional in vitro experiments supporting a
direct stimulatory effect of triflusal on insulin release from
beta cells [33].
Normalisation for insulin concentration reflects the fact
that whole-body glucose uptake progressively increases
with higher rates of insulin infusions and the consequent
rise in systemic insulin concentrations within the high
physiological range [29, 34, 35]. In our study, Rd was
clearly higher following salsalate administration, but nor-
malisation to serum insulin concentrations completely
eliminated this difference. It must be noted that in prior
studies showing improved insulin action after aspirin in
humans the authors either did not report insulin concen-
trations [18] or did not normalise the Rd, which was higher
after aspirin treatment compared with baseline, to insulin
concentrations [12]. In the latter study, the investigators did
perform additional clamp studies in a small subgroup of
participants with type 2 diabetes matching the insulin
concentrations during clamps performed on and off treat-
ment with aspirin [12]. In this sub-study, they did find an
increase in glucose disposal, indicating that the improve-
ment of insulin action might be independent of systemic
insulin concentration. The mechanism, however, may not
be an anti-inflammatory effect, but could have been
secondary to decreased glycaemia.
Although our results showed that the increase in Rd was
due entirely to an increase in insulin concentrations,
previous experimental data have indicated that the
glucose-lowering effect of salicylates was due to improved
insulin sensitivity resulting from inhibition of IKKβ/NF-κB
pathway activity and the consequent decrease in production
of pro-inflammatory cytokines interfering with insulin
action [15, 16, 23, 24, 36]. Genetic or pharmacological
manipulation of IKKβ/NF-κB pathway activity at whole-
body or tissue level in experimental animal models was
associated with improved peripheral and hepatic insulin
action on glucose metabolism [15–17, 25, 37]. However,
muscle-specific inhibition of the IKKβ/NF-κB pathway
had no effect on a high-fat-induced impairment in periph-
eral insulin action, while the deletion of IKKβ in the
myeloid/monocyte cell line did [36]. Consistent with this
finding, the NF-κB activity in isolated monocytes nega-
tively correlated with glucose uptake in a subset of
individuals in our study. However, it was unchanged after
1 week of treatment with salsalate. Lack of significant
effect of salsalate on plasma glucose concentration in this
subset (although the direction of the effect was the same)
and the relatively small numbers make some caution
necessary when interpreting these data.
We cannot rule out the possibility that with a higher dose
and/or longer treatment we might have observed inhibition
of NF-κB activity and a possible improvement of insulin
action via this pathway. The salicylate concentrations in our
study were below those reported in the study describing
improvement of insulin action in participants with type 2
diabetes after 2 weeks of treatment with, on average, 6.2 g
of daily aspirin [12]. We did, however, find that changes in
glucose disposal positively correlated with follow-up
salicylate levels in participants receiving salsalate. This
association indicates that at higher serum salicylate con-
centrations improvements in insulin action may be partially
mediated by pathways (such as NF-κB) other than
increased concentrations of insulin in the circulation.
However, as the salicylate concentration achieved during
treatment was not a randomised feature of the present study,
potential confounding factors in this association are hard to
exclude. The findings from the randomised treatment
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suggest that altered insulin clearance (or secretion) is the
primary, clinically meaningful mediator of improvement in
glycaemia and increase in Rd. Should salicylates at high
concentrations improve insulin action, the clinical relevance
of this is unclear.
Experiments in rodents have shown that liver-specific
inhibition of the IKKβ/NF-κB pathway [36] and treatment
with salicylates [17] prevented hepatic insulin resistance.
The dose of insulin used in our study was too high to
accurately estimate hepatic insulin action. Almost half of all
participants in both groups had complete suppression of
EGP at baseline and follow-up.
A recent study reported that improvement of glucose
tolerance after 4 weeks of treatment with salsalate was
accompanied by a significant increase in plasma adiponec-
tin concentration [13]. In our study, adiponectin concen-
trations were unchanged compared with significant
reductions in the placebo group. It is possible that a
decrease in physical activity (activities in our inpatient unit
during the study are restricted, so participants are more
sedentary than in free-living conditions) accounted for the
decline in adiponectin concentrations in the placebo, but
this was prevented by administration of salsalate.
In conclusion, the results of our study indicate that the
primary mechanism for the glucose-lowering effect of a
common dose of salicylates appears to be alterations in
systemic insulin concentrations. Since reduction of glycae-
mia is the ultimate goal of treatment and prevention of
diabetes, salicylate-based compounds may have potential
for treatment or prevention of type 2 diabetes. However, the
mechanism by which salicylates increase insulin concen-
tration and lower glucose remains to be determined.
Furthermore, the glucose-lowering efficacy of a potential
salicylate therapy would assume that the favourable
metabolic effects of salicylates would be maintained over
a long period of time.
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